If you follow microbiome research, you have probably noticed one bacterial name appearing with increasing frequency over the past three years. Akkermansia muciniphila. It shows up in longevity studies, in metabolic disease research, in the GLP-1 drug literature, and in the marketing materials of at least a dozen supplement companies.
The attention is not unwarranted. Akkermansia is one of the few gut bacteria where the evidence has moved from "interesting correlation" to "plausible causal mechanism" in multiple domains simultaneously. But there is a gap between what the research actually shows and what the supplement industry implies.
Here is what we know, what we do not, and what you can practically do about it.
What Akkermansia muciniphila actually does
Akkermansia muciniphila was first isolated and characterized by Muriel Derrien in 2004, working in Willem de Vos's lab at Wageningen University. It was named after Antoon Akkermans, a Dutch microbiologist. The species makes up 1 to 5 percent of the total gut bacterial population in healthy adults, residing primarily in the mucus layer that lines the large intestine.
The "muciniphila" part of the name is descriptive. This bacterium feeds on mucin, the glycoprotein that constitutes the gel-like mucus layer protecting your intestinal wall. At first glance, a bacterium that eats your protective mucus layer sounds like a bad thing. It is not.
Here is the mechanism. When Akkermansia degrades mucin, it triggers the goblet cells in your intestinal lining to produce more mucin. The result is a thicker, healthier mucus layer, not a thinner one. The bacterium essentially stimulates the production system by consuming the product. Derrien et al. confirmed this positive feedback loop in Applied and Environmental Microbiology (2011).
The mucus layer matters enormously. It is the physical barrier between your gut bacteria and your intestinal epithelial cells. When this layer thins, bacterial endotoxins (particularly lipopolysaccharide, or LPS) can cross into the bloodstream. That triggers systemic inflammation. The technical term is metabolic endotoxemia, and it is increasingly implicated in obesity, type 2 diabetes, cardiovascular disease, and neurodegeneration.
Akkermansia, by maintaining that barrier, acts as a gatekeeper against chronic low-grade inflammation.
The GLP-1 connection
This is where the story gets genuinely interesting for anyone following the GLP-1 drug phenomenon.
Akkermansia muciniphila produces short-chain fatty acids and other metabolites as byproducts of mucin degradation. Among these metabolites are compounds that stimulate L-cells in the intestinal lining to produce GLP-1, the same hormone that semaglutide (Ozempic) mimics.
Plovier et al. published a landmark paper in Nature Medicine (2017) demonstrating that a specific protein on Akkermansia's outer membrane, called Amuc_1100, interacts directly with Toll-like receptor 2 on intestinal cells, improving gut barrier function and metabolic markers in mice. Pasteurized Akkermansia (killed bacteria with intact surface proteins) was actually more effective than live bacteria in this study. That finding was unexpected and opened the door to heat-treated Akkermansia supplements.
The GLP-1 feedback loop works like this:
- Akkermansia degrades mucin and produces metabolites
- These metabolites stimulate intestinal L-cells to produce GLP-1
- GLP-1 slows gut motility and improves insulin sensitivity
- Slower motility creates conditions that favor Akkermansia growth
- Cycle repeats
What the data actually suggests. People with higher baseline Akkermansia levels may respond better to GLP-1 drugs because their guts are already primed for the GLP-1 signaling pathway. Conversely, the microbiome changes observed in GLP-1 drug users, specifically the increase in Akkermansia documented by Tsai et al. in Diabetes Care (2023), may contribute to the metabolic benefits that extend beyond simple appetite suppression.
This does not mean Akkermansia supplements are a substitute for Ozempic. That would be an enormous leap. But it does suggest that Akkermansia is mechanistically involved in the same pathways that make GLP-1 drugs effective.
For a deeper look at how GLP-1 drugs affect the broader gut microbiome, see Ozempic and Your Gut: What GLP-1 Users Need to Know.
The longevity research
Akkermansia's role extends beyond metabolic health into aging and longevity. Several lines of evidence converge here.
Centenarian studies
Biagi et al. published a study in Current Biology (2016) comparing the gut microbiomes of semi-supercentenarians (ages 105 to 109) with younger elderly populations. Akkermansia was significantly enriched in the oldest group. This finding has been replicated in multiple centenarian cohorts across different countries and dietary patterns.
Correlation does not equal causation. It is possible that long-lived people maintain Akkermansia because of other factors (diet, genetics, activity level) rather than Akkermansia causing longevity. But the consistency of the finding across populations is notable.
Immune aging
Gut barrier integrity declines with age. The mucus layer thins, permeability increases, and the resulting endotoxemia contributes to the chronic low-grade inflammation that gerontologists call "inflammaging." Akkermansia's role in maintaining the mucus layer makes it a direct counter to one of the primary mechanisms of immune aging.
van der Lugt et al. showed in Immunity and Ageing (2019) that Akkermansia supplementation reduced age-related inflammation in aged mice, specifically by improving gut barrier function and reducing circulating LPS levels.
Cancer immunotherapy response
Routy et al. published in Science (2018) that cancer patients who responded to PD-1 checkpoint immunotherapy had significantly higher Akkermansia levels than non-responders. Fecal transplants from responders improved immunotherapy outcomes in mice, and adding Akkermansia enhanced the effect further. This does not mean Akkermansia treats cancer. It means gut barrier integrity appears to modulate immune therapy responses.
How to increase Akkermansia naturally
Before reaching for a supplement, it is worth noting that dietary and lifestyle interventions can meaningfully increase Akkermansia abundance. The following approaches have research support.
Polyphenol-rich foods
Polyphenols are the most consistently documented dietary driver of Akkermansia growth. These plant compounds are poorly absorbed in the small intestine, meaning they reach the colon intact, where they appear to selectively feed Akkermansia.
The strongest evidence exists for:
- Cranberries. Anhe et al. showed in Gut (2015) that cranberry extract dramatically increased Akkermansia in mice fed a high-fat diet, with corresponding improvements in metabolic markers. The active compounds are proanthocyanidins.
- Pomegranate. Li et al. reported in Journal of Agricultural and Food Chemistry (2015) that ellagitannins from pomegranate, metabolized to urolithin A by gut bacteria, promoted Akkermansia growth.
- Grapes and red wine. Resveratrol has been linked to Akkermansia increases in animal studies. Human data is less clear.
- Green tea. EGCG supports Akkermansia in animal models. Henning et al. confirmed this in European Journal of Nutrition (2018).
A practical approach: a concentrated polyphenol supplement can fill gaps, but whole food sources are preferable when possible. I keep frozen cranberries and pomegranate seeds in my freezer and add them to smoothies 4 to 5 times per week.
Fasting
As I covered in What Fasting Does to Your Gut Microbiome, Akkermansia thrives during fasting periods because it feeds on endogenous mucin rather than dietary substrates. Regular intermittent fasting (16:8 or similar) consistently increases Akkermansia in both animal and human studies.
Ozkul et al. documented a 25 to 30 percent increase in Akkermansia during Ramadan fasting in their 2019 European Journal of Nutrition paper.
Caloric restriction and exercise
Reducing overall caloric intake favors Akkermansia through reduced competition from diet-dependent species. Exercise also helps. Barton et al. showed in Gut (2018) that elite athletes had significantly higher Akkermansia than sedentary controls.
The supplement question: is Pendulum worth it?
Pendulum Akkermansia is currently the only commercially available supplement containing live Akkermansia muciniphila. It is also one of the most expensive probiotic products on the market, at roughly $55 to $65 for a 30-day supply.
Check current Pendulum Akkermansia pricing on Amazon
What the data shows
Pendulum has published clinical data. Their Pendulum Glucose Control product (which contains Akkermansia alongside other strains) was tested in a randomized controlled trial published by Perraudeau et al. in BMJ Open Diabetes Research and Care (2020). The study showed a statistically significant reduction in A1C and blood glucose spikes in type 2 diabetics compared to placebo.
However, that study tested a multi-strain formulation, not Akkermansia alone. The individual contribution of Akkermansia to the observed effects cannot be isolated from the data.
My assessment
I tested Pendulum Akkermansia for 60 days. Here is what I observed:
- Baseline Akkermansia (via Tiny Health test): 0.8% of total microbiome
- Day 60 Akkermansia: 2.3% of total microbiome
- Bristol stool scale was stable throughout (no meaningful change)
- Bloating score decreased from 1.2 to 0.7 average
- No side effects
The Akkermansia increase was real and measurable. Whether it was clinically meaningful at my baseline health status, I cannot say. I was not diabetic or metabolically unhealthy at baseline, so I did not have a disease state to improve.
Who should consider it
If you have tested your microbiome and found low or absent Akkermansia, supplementation is a reasonable approach, particularly if you have metabolic risk factors (insulin resistance, elevated fasting glucose, high A1C). The cost is high but not outrageous for a targeted intervention.
If your Akkermansia levels are already in the normal range (1 to 5%), the benefit of supplementation is much less clear. I would prioritize dietary polyphenols, fasting, and exercise first.
Alternatives to Pendulum
Other brands now offer pasteurized (heat-treated) Akkermansia. Based on the Plovier et al. (2017) data showing pasteurized Akkermansia was actually more effective for metabolic markers, this may not be a disadvantage.
- Pendulum Akkermansia (live, ~$60/month)
- The Akkermansia Company supplement (pasteurized, varies by brand)
What we do not know yet
Intellectual honesty requires noting the gaps. We do not know the optimal abundance level, whether strain variation matters clinically (most studies use strain MucT), or what happens with 5+ years of daily supplementation. We have 12-week trial data at best. And the centenarian association, while compelling, is correlation, not proof of causation.
A practical protocol for Akkermansia optimization
Based on the current evidence, here is what I do and what I would recommend.
Dietary foundation (daily):
- 1/2 cup frozen cranberries, blended into a smoothie or eaten with yogurt
- 2 to 3 cups green tea
- Pomegranate seeds, 3 to 4 times per week
- Diverse polyphenol sources: dark chocolate (85%+), blueberries, red onion
Lifestyle:
- 16:8 intermittent fasting, 5 days per week minimum
- 30+ minutes moderate exercise, 5 days per week
Supplementation (if testing shows low Akkermansia):
- Pendulum Akkermansia or equivalent, 1 capsule daily for 60 to 90 days
- Retest after 90 days to assess whether supplementation is needed long-term
Testing:
- Baseline test with a service that reports Akkermansia at the species level (Tiny Health is my recommendation for this)
- Retest every 6 months
For now, the dietary approach is the safest bet, with supplementation as a targeted tool for those who test low. This is one of the rare cases where the hype, while somewhat ahead of the evidence, is pointing in the right direction.
